Stocktoria

ACCURAY INC ARAY

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2007-02-08 · LEI

ACCURAY INC (ARAY) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $458.5M at a -0.3% net margin.

Chart by TradingView
36/100
Stocktoria Quality Score · grade D
6/9
Piotroski F — financial health
-1.53
Altman Z″ — distress risk · distress
Dividend yield · no dividend
-2.56
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 3 7 2 4 5 3 5 3 6 2016201720182019202020212022202320242025
Altman Z″
-0.72 -3.24 -2.01 -1.19 -0.53 -0.63 -1.18 -1.34 -1.69 -1.53 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$0.28 as of 2026-08-01 · -81.6% 1y
$0.26$1.6752-wk

Beneish M-score: -2.56 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$31M
Net margin 5y avg-1.7%
Return on equity 5y avg-14.6%
Beta1.35
Employees990

Analyst price target

$0.35 +25% vs last
· 1 analysts
target range $0.35 – $0.35

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$134,675 on the open market · 3 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 53%
Return on equitystronger than 56%
Revenue growthstronger than 43%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.266
Retained earnings / assets-1.104
EBIT / assets0.017
Equity / liabilities0.209

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ARAYACCURAY INC6/9-1.53+2.7%
AORTARTIVION, INC.7/93.05117.3+13.6%
MDXGMIMEDX GROUP, INC.5/98.0612+20%
GKOSGLAUKOS Corp2/90.74+32.3%
ATRCAtriCure, Inc.7/93.44+14.9%
BVSBioventus Inc.8/90.5435.9-0.9%
TCMDTACTILE SYSTEMS TECHNOLOGY INC7/98.5235.8+12.5%

All Manufacturing companies →

About ACCURAY INC

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

FAQ

Is ARAY financially healthy?

ACCURAY INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does ARAY pay a dividend?

No, ACCURAY INC does not currently pay a dividend.

How profitable is ARAY?

In FY2025, ACCURAY INC had a net margin of -0.3% and a return on equity of -2.0%.

What is the analyst price target for ARAY?

The average Wall-Street price target for ACCURAY INC is $0.35, about 25.0% above the recent price, from 1 analysts.

Is ARAY a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ACCURAY INC: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.